» Articles » PMID: 15543157

Structures of Human MAP Kinase Kinase 1 (MEK1) and MEK2 Describe Novel Noncompetitive Kinase Inhibition

Abstract

MEK1 and MEK2 are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway. Approximately 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation. Here we present the X-ray structures of human MEK1 and MEK2, each determined as a ternary complex with MgATP and an inhibitor to a resolution of 2.4 A and 3.2 A, respectively. The structures reveal that MEK1 and MEK2 each have a unique inhibitor-binding pocket adjacent to the MgATP-binding site. The presence of the potent inhibitor induces several conformational changes in the unphosphorylated MEK1 and MEK2 enzymes that lock them into a closed but catalytically inactive species. Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.

Citing Articles

Exploring the inhibitory potential of xanthohumol on MEK1/2: a molecular docking and dynamics simulation investigation.

Gholizadeh Siahmazgi Z, Irani S, Ghiaseddin A, Soutodeh F, Gohari Z, Afifeh J Res Pharm Sci. 2025; 19(6):669-682.

PMID: 39911899 PMC: 11792713. DOI: 10.4103/RPS.RPS_38_24.


Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.

Leguay K, Kent O Onco Targets Ther. 2025; 18:147-159.

PMID: 39882405 PMC: 11776410. DOI: 10.2147/OTT.S496228.


Identification of a Novel 4-gene Prognostic Model Related to Neutrophil Extracellular Traps for Colorectal Cancer.

Qian J, Duan J, Cao D Turk J Gastroenterol. 2024; 35(11):849-858.

PMID: 39549020 PMC: 11562497. DOI: 10.5152/tjg.2024.24131.


A Bioinformatic Analysis Predicts That Cannabidiol Could Function as a Potential Inhibitor of the MAPK Pathway in Colorectal Cancer.

du Plessis J, Deroubaix A, Omar A, Penny C Curr Issues Mol Biol. 2024; 46(8):8600-8610.

PMID: 39194723 PMC: 11352951. DOI: 10.3390/cimb46080506.


Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.

Chaudhary H, Cannon T, Winer A Drugs R D. 2024; 24(3):395-403.

PMID: 39177935 PMC: 11455815. DOI: 10.1007/s40268-024-00475-5.